JNJ Continues to Grow AD Pipeline With New Licensing Agreement
The Dermatology Digest
DECEMBER 27, 2024
Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical. the venture capital organization of Johnson & Johnson.
Let's personalize your content